Macadamia Nut-Specific IgE Levels Predict Anaphylaxis
By LabMedica International staff writers Posted on 24 Oct 2022 |
Proteins residing in tree nuts are mistakenly treated as harmful by the immune system, which then releases antibodies to combat them. Chemical reaction triggers within protein substances, mast cells and histamines produced by immune system resulting in allergic symptoms.
Tree nut allergy symptoms typically occur within minutes of ingestion and can range from hives to anaphylaxis, a potentially life-threatening reaction that impairs breathing and can send the body into shock. In terms of prevalence, less than 5% of people in the USA who are sensitized to tree nuts are allergic to macadamia nuts.
Allergists and immunologists from the Sagamihara National Hospital (Sagamihara, Japan) included in a study 41 children (71% boys; median age, 7.7 years) with suspected macadamia nut allergy who visited the hospital between April 2012 and July 2021. Patient interviews and a three-level stepwise oral food challenge (OFC) found that 21 of these children had an allergy and 20 did not. The study aimed to investigate macadamia nut-specific immunoglobulin E (Md-sIgE).
Eight of the allergic children (38%) had experienced anaphylaxis. Symptoms included generalized urticaria, cough, wheezing, throat pruritus, abdominal pain, lip swelling and recurrent emesis. Among the other 13 allergic children (62%) who did not experience anaphylaxis, symptoms included face swelling, localized or generalized urticaria, intermittent cough, lip swelling and throat pruritus. None of the allergic children experienced mild subjective symptoms that were localized to the oral cavity.
The investigators collected blood samples from all patients within 12 months of the OFC or the allergic reaction to macadamia nut. The median level of macadamia nut-specific IgE (Md-sIgE) for the full cohort was 2.23 kUA/L. The children with allergy and anaphylaxis had higher Md-sIgE levels (median, 7.97 kUA/L; interquartile range [IQR], 5.08-23.3) than the children with allergy who did not have anaphylaxis (median, 1.92 kUA/L; IQR, 0.83-6.04) and those who did not have allergy (median, 1.9 kUA/L; IQR, 0.56-2.78). The difference between the latter two groups did not reach significance.
Based on receiver operating characteristic analysis for predicting anaphylaxis using Md-sIgE levels, the researchers found that the area under the curve of Md-sIgE was 0.92 (95% CI, 0.83-1) with an optimal cutoff value of 3.76 kUA/L. Eight of the 16 children (50%) with Md-sIgE levels over this level and none of the children with levels under that benchmark developed anaphylaxis.
Also, positive predictive values for anaphylaxis included 5% for 1.8 kUA/L, 10% for 2.75 kUA/L, 20% for 4.36 kUA/L, 80% for 21.06 kUA/L, 90% for 33.38 kUA/L and 95% for 51.04 kUA/L, with a maximum value of 38.3 kUA/L. About one-third of the children with sIgE values under 3.76 kUA/L had a macadamia nut allergy with no anaphylaxis, indicating that OFC could be safe for them.
The authors concluded that Md-sIgE levels were useful in predicting anaphylaxis. Above the cut-off value, they emphasized paying careful attention to the risk of anaphylaxis. The study was first published on September 18, 2022 in the journal Pediatric Allergy and Immunology.
Related Links:
Sagamihara National Hospital
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms